Update Note
Withdrawing fair value range
Klas Palin
2026-11-20
12:46 CET
Given DNB Carnegie’s role in the recently announced share issue, we withdraw our fair value range on Lytix Biopharma. Our estimates and fair value range have not been updated and should no longer be relied upon.
Capital raise completed. On 18 November, the company announced the successful completion of a private placement and retail offering, raising gross proceeds of NOK80m at a share price of NOK8.00 and implying dilution of around 12%. Several of its largest shareholders and members of management participated in the private placement.
Subsequent offering. In addition to the private placement and retail offering, the board of directors has resolved to conduct a subsequent offering of new shares at the same offer price, raising gross proceeds of up to NOK15m. The offering is intended to mitigate the dilutive effect of the earlier transactions and, subject to applicable securities laws, will be directed at existing shareholders as of 17 November 2026. However, according to the company’s press release, the company may, in consultation with its advisors, decide not to proceed if its shares trade at or below the subscription price at sufficient volumes.
Use of proceeds. Net proceeds from the completed private placement and retail offering are intended to be used to support Phase III readiness for ruxotemitide, fund Lytix share of costs related to the investigator-led Phase II ALETTA study, advance LTX-401 towards Phase I development, and for general corporate purposes and working capital.